Navigation Links
aTyr Pharma Secures $23M Financing From Top Tier Venture Investor
Date:10/26/2010

SAN DIEGO, Oct. 26 /PRNewswire/ -- aTyr Pharma, the physiocrine therapeutics company, today announced a $23 million Series C equity financing led by Domain Associates.  Domain joins existing venture investors Alta Partners, Cardinal Partners and Polaris Ventures, who also participated in the financing.  Proceeds will be used to accelerate the development of aTyr's preclinical pipeline and advance physiocrine drug candidates into clinical trials.  Physiocrines are a recently elucidated class of endogenous human proteins that function as extracellular signaling molecules in a variety of physiologic settings.  As either therapeutic proteins or as targets for antibodies, physiocrines have the potential to address a wide range of diseases, including high unmet patient needs in blood, immune, and metabolism disorders.

"Physiocrines offer a completely new set of physiologic extracellular pathways for developing novel therapeutics.  These natural human proteins function in normal and pathologic settings, yet act via mechanisms that are differentiated and potentially superior from other therapeutic approaches," said James C. Blair, Ph.D., Partner at Domain Associates.  "We believe multiple products within aTyr's portfolio offer promise for fundamentally improved patient care while achieving attractive commercial goals.  We are enthusiastic to work with aTyr's leadership team and existing syndicate to build a world class protein therapeutics enterprise."  

"Attracting investors with a successful track record in protein therapeutics further re-enforces the therapeutic promise of our new class of human proteins, physiocrines.  As the exclusive developer of physiocrine-based therapeutics, aTyr is well positioned by this recent financing to further build a strong, sustainable pipeline of innovative medicines for patients," said Jeff Watkins, Ph.D., Chief Executive Officer of aTyr Pharma.  "Our initial physiocrine
'/>"/>

SOURCE aTyr Pharma
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Biostar Pharmaceuticals, Inc. Expands Rural Network by Over 21% in Third Quarter 2010; Brings Total Number of Locations to 8,500
2. OncoGenex Pharmaceuticals, Inc. Closes $50 Million Public Offering
3. A New BioPharma Intelligence Resource Set to Give Industry Leaders the Edge
4. Access Pharmaceuticals Files Additional IP For Cobalamin Oral Delivery Technology
5. Amylin Pharmaceuticals Announces Third Quarter Product Revenues; Quarterly Update Conference Call Canceled
6. Reportlinker Adds Downstream Processing in Biopharmaceuticals - Increased Demand for Biologics Drives Improvement in Cost -effective Purification Technologies
7. OncoGenex Pharmaceuticals, Inc. Prices $50 Million Public Offering
8. Lotus Pharmaceuticals Announces New Patent for Controlled-Release Diabetes Drug
9. OncoGenex Pharmaceuticals, Inc. Announces Proposed Public Offering
10. ANGIOTECH PHARMACEUTICALS ANNOUNCES CONFERENCE CALL AND WEBCAST
11. Biopharma Leaders to Reveal Successful Strategies for China, India at the PharmAsia Summit in San Francisco
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... - Sunovion Pharmaceuticals Canada Inc. (Sunovion) today announced that ... use as a once-daily adjunctive therapy for the treatment ... not satisfactorily controlled with conventional therapy.  APTIOM TM ... years of age. Epilepsy is one ... Epilepsy Canada, it affects 0.6% of the population and ...
(Date:7/10/2014)... Burkina Faso (PRWEB) July 10, 2014 ... Faso, today have access to an additional family ... increase access to contraception at all levels of ... a lower-dose formulation of a widely used contraceptive—Pfizer’s ... system. , Burkina Faso is the first of ...
(Date:7/10/2014)... Cleveland, Ohio (PRWEB) July 10, 2014 ... in ion channel-expressing cell lines, and the gap that ... new cells that expand its industry-leading portfolio of validated ... focuses on ion channel-expressing cell lines, as ion channels ... able to control this activity creates the potential to ...
(Date:7/10/2014)... (PRWEB) July 10, 2014 Robert Harman, DVM, ... Medicine company, is proud to announce the relaunch of his ... with a new series called “ What are Stem Cells ... an honest and straightforward foundation in the basics of stem ... decision on the right type of treatment when considering regenerative ...
Breaking Biology Technology:Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 2Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 3Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 4Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 2Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 3Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 4Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 5Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 6Leader in Ion Channel Research Announces Newly Validated and Re-Engineered Cells 2Leader in Ion Channel Research Announces Newly Validated and Re-Engineered Cells 3Robert Harman, DVM Talks About What Stem Cells are in His Latest Blog Series for Vet-Stem, Inc. 2Robert Harman, DVM Talks About What Stem Cells are in His Latest Blog Series for Vet-Stem, Inc. 3
... 15, 2011 Reportlinker.com announces that a ... its catalogue: India Biotechnology ... http://www.reportlinker.com/p0553099/India-Biotechnology-in-India-Industry.html?utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_Disc This report analyzes ... US$ million by the following Key Sectors ...
... NEW BRUNSWICK, N.J., June 14, 2011 Psoriasis is ... of the world,s population or more than 125 million ... others, it is disabling. On a continuing ... an article published in the Journal of Investigative ...
... Inc. , a California-based clean technology company serving the ... yeast technology from the USDA Forest Products Laboratory (FPL) ... the fermentation of C5 sugars, such as xylose, to ... Cooperative Research and Development Agreement (CRADA) between FPL and ...
Cached Biology Technology:Reportlinker Adds India Biotechnology in India Industry 2Reportlinker Adds India Biotechnology in India Industry 3Reportlinker Adds India Biotechnology in India Industry 4Reportlinker Adds India Biotechnology in India Industry 5Reportlinker Adds India Biotechnology in India Industry 6Reportlinker Adds India Biotechnology in India Industry 7Reportlinker Adds India Biotechnology in India Industry 8Reportlinker Adds India Biotechnology in India Industry 9Reportlinker Adds India Biotechnology in India Industry 10Reportlinker Adds India Biotechnology in India Industry 11Reportlinker Adds India Biotechnology in India Industry 12Actinobac Biomed, Inc. Demonstrates In Vivo Efficacy for Psoriasis Treatment 2EdeniQ Licenses Yeast Technology from USDA 2
(Date:7/11/2014)... from the Max Planck Institute for Medical Research in ... understanding photosynthesis, the process by which the Earth first ... and which is therefore crucial for all higher forms ... the first direct visualization of a crucial event in ... specific protein complex, photosystem II, splits water into hydrogen ...
(Date:7/11/2014)... marginal division of the striatum is also involved ... degree of substance P in the striatal marginal ... and his team, College of Biophotonics, South China ... substance P receptor, neurokinin 1 was highly expressed ... normal rats. Unilateral or bilateral injection of an ...
(Date:7/11/2014)... Rio de Janeiro, Brazil- In the brains of ... mechanism that allows an electric or chemical signal ... another. Chemical synapses, which are the most abundant ... inhibitory. Synapse formation is crucial for learning, memory, ... and inhibitory synapses critical for brain function. ...
Breaking Biology News(10 mins):A first direct glimpse of photosynthesis in action 2Blame it on the astrocytes 2
... French . Researchers at the Montreal ... basis of depression in male athletes with persisting post-concussion ... Archives of General Psychiatry, has important clinical implications for ... concussion. Depression is one of a number ...
... release is also available in German . ... modified bacteria produce human insulin. In future, gene therapy should ... a diseased organism so that they can address deficiencies to ... to work, foreign (or synthetic) DNA must be introduced into ...
... the interaction of genes and environment in the ... King,s College London, has been awarded the Mortimer ... Developmental Psychobiology. Presented jointly by the Sackler Institute ... and the Sackler Institute for Developmental Psychobiology at ...
Cached Biology News:MNI researchers locate neurological basis of depression following sports concussion 2Cells get sprayed 2Research pioneer in the developmental origins of psychiatric illness is awarded the Sackler prize 2
MHC Volumes 1 & 2...
BD IMagnet 1 each...
Vertical Rack (five box vapor phase rack), includes 2.0" (5.1cm) boxes...
... M.W. Turner (1997). • This book ... in the production of high-quality antibodies, ... the standardisation of antibodies and antigens, ... systems, enzyme immunoassays for detecting cell-surface ...
Biology Products: